



Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

Henning Gall¹ · Jean-Luc Vachiéry² · Nobuhiro Tanabe³ · Michael Halank⁴ · Mauricio Orozco-Levi⁵ · Lisa Mielniczuk⁶ · MiKyung Chang⁷ · Kai Vogtländer⁸ · Ekkehard Grünig⁹

Published online: 3 April 2018
© The Author(s) 2018

Correction to: Lung
<https://doi.org/10.1007/s00408-018-0100-3>

The original version of this article unfortunately contained a mistake. In the “Results” section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.

The original article can be found online at <https://doi.org/10.1007/s00408-018-0100-3>.

✉ Henning Gall
Henning.Gall@innere.med.uni-giessen.de

¹ Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Klinikstrasse 32, 35392 Giessen, Germany

² Département de Cardiologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium

³ Department of Respiriology and Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University, Chiba, Japan

⁴ Medical Clinic I/Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany

⁵ Hospital Internacional de Colombia, Fundación Cardiovascular de Colombia, Santander, Colombia

⁶ University of Ottawa Heart Institute, Ottawa, ON, Canada

⁷ Bayer AG, Berlin, Germany

⁸ Bayer AG, Wuppertal, Germany

⁹ Center for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany